Orasis Pharmaceuticals Presents New Data Showing Qlosi Is Pupil Selective in Presbyopic Eyes

Orasis Pharmaceuticals announced new clinical data demonstrating that Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% is pupil selective, significantly reducing pupil diameter without a statistically significant change in ciliary muscle response in presbyopic eyes.

Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals, said “We believe this further illustrates why formulation matters and why the concentration-dependent effects demonstrated by Qlosi reinforce how our product was designed with the safety of the presbyopia patient in mind.”

Read more.